Skip to main content
. 2021 Dec 2;2021:2497227. doi: 10.1155/2021/2497227

Table 1.

Baseline characteristics according to treatment regimens.

Characteristics n MAST (%) MAST + RT (%) LUMP (%) LUMP + RT (%) p
Year of study
 1983–1993 56 38 (15.0%) 6 (7.7%) 7(8.0%) 5 (5.2%) 0.012
 1994–2004 209 103 (40.6%) 28 (35.9%) 29 (33.3%) 49(51.0%)
 2005–2016 250 113 (44.5%) 44 (56.4%) 51 (58.6%) 42 (43.8%)
Age (years)
 ≤50 93 31 (12.2%) 23 (29.5%) 17 (19.5%) 22 (22.9%) 0.002
 >50 422 223 (87.8%) 55 (70.5%) 70 (80.5%) 74 (77.1%)
Race
 Black 59 29 (11.4%) 8 (10.3%) 10 (11.5%) 12 (12.5%) 0.99
 White 433 212 (83.5%) 67 (85.9%) 73 (83.9%) 81 (84.4%)
 Others 23 13 (5.1%) 3 (3.8%) 4 (4.6%) 3 (3.1%)
TNM stage
 I 95 29 (11.4%) 2 (2.5%) 34 (39.1%) 30 (31.3%) <0.001
 II 243 131 (51.6%) 37 (47.4%) 32 (36.8%) 43 (44.8%)
 III 91 47 (18.5%) 30 (38.5%) 5 (5.7%) 9 (0.4%)
 Unknown 86 47 (18.5%) 9 (11.5%) 16 (18.4%) 14 (14.6%)
Tumor stage (n = 429)
 T1 108 35 (13.8%) 4 (5.1%) 35 (40.2%) 34 (35.4%) <0.001
 T2 195 105 (41.3%) 27 (34.6%) 29 (33.3%) 34 (35.4%)
 T3 75 40 (15.7%) 20 (25.6%) 3 (3.4%) 12 (12.5%)
 T4 51 27 (10.6%) 18 (23.1%) 4 (4.6%) 2 (2.1%)
 Unknown 86 47 (18.5%) 9 (11.5%) 16 (18.3%) 14 (14.6%)
Nodal stage
 N0 322 156 (61.4%) 39 (50%) 62 (71.3%) 65 (67.7%) 0.002
 N1 72 32 (12.6%) 22 (28.2%) 6 (6.9%) 12 (12.5%)
 N2 21 11 (4.3%) 7 (9.0%) 1 (1.1%) 2 (2.1%)
 N3 10 6 (2.4%) 1 (1.3%) 0 3 (3.1%)
 Unknown 90 49 (19.3%) 9 (11.5%) 18 (20.7%) 14 (14.6%)
ER status
 Positive 71 39 (15.4%) 11 (14.1%) 9 (10.3%) 12 (12.5%) 0.01
 Negative 303 139 (54.7%) 53 (67.9%) 44 (50.6%) 67 (69.8%)
 Unknown 141 76 (29.9%) 14 (17.9%) 34 (39.1%) 17 (17.7%)
PR status
 Positive 42 15 (5.9%) 11 (14.1%) 6 (6.9%) 10 (10.4%) 0.01
 Negative 327 159 (62.6%) 53 (67.9%) 48 (55.2%) 67 (69.8%)
 Unknown 146 80 (31.5%) 14 (17.9%) 33 (37.9%) 19 (19.8%)
Grade
 Well-differentiated 50 22 (33.3%) 7 (33.3%) 14 (41.2%) 7 (24.1%) 0.29
 Moderately differentiated 122 66 (66.7%) 14 (66.7%) 20 (58.8%) 22 (75.9%)
 Poor or undifferentiated 253 117 (70.5%) 47 (82.5%) 40 (75.5%) 49 (73.1%)
 Unknown 90 49 (29.5%) 10 (17.5%) 13 (24.5%) 18 (26.9%)
Chemotherapy
 Yes 206 86 (33.9%) 54 (69.2%) 17 (19.5%) 49 (51.0%) <0.001
 No/unknown 309 168 (66.1%) 24 (30.8%) 70 (80.5%) 47 (49.0%)

MAST, mastectomy; LUMP, lumpectomy; RT, radiotherapy; ER, estrogen receptor; PR, progesterone receptor.